Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02378714 · ClinicalTrials.gov registry record · Phase 4
Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT02378714 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 300 participants.
The verdict
NCT02378714, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown. The proposed trial tests whether the combination of varenicline and behavioral mood management treatment enhances long-term abstinence for depressed smokers and, if so, whether this treatment achieves its effects through addressing the unique psychological factors that appear to maintain tobacco dependence for these smokers.
Interventions
- DRUG Varenicline
- BEHAVIORAL Standard treatment
- BEHAVIORAL BASC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2015-07-24 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02378714
The ClinicalTrials.gov registry entry for NCT02378714 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT02378714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02378714 about?
NCT02378714 is a clinical study titled "Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers". Persons who struggle with depression smoke at high rates and experience low quit rates in treatment. The best way to improve cessation treatment for this underserved population remains unknown. The proposed trial tests whether the combination of varenicline and behavioral mood management treatment e...
What is the current status of trial NCT02378714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2015-07-24. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT02378714?
The interventions under investigation include: Varenicline (DRUG), Standard treatment (BEHAVIORAL), BASC (BEHAVIORAL).
Who is sponsoring clinical trial NCT02378714?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.